- Home
- PSF vs PLX Comparison
PSF vs PLX Comparison
Compare PSF & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- PLX
- Stock Information
- Founded
- PSF 2010
- PLX 1993
- Country
- PSF United States
- PLX United States
- Employees
- PSF N/A
- PLX N/A
- Industry
- PSF Investment Managers
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSF Finance
- PLX Health Care
- Exchange
- PSF Nasdaq
- PLX Nasdaq
- Market Cap
- PSF 251.0M
- PLX 204.9M
- IPO Year
- PSF N/A
- PLX 1998
- Fundamental
- Price
- PSF $20.02
- PLX $1.74
- Analyst Decision
- PSF
- PLX Strong Buy
- Analyst Count
- PSF 0
- PLX 1
- Target Price
- PSF N/A
- PLX $12.00
- AVG Volume (30 Days)
- PSF 25.0K
- PLX 632.5K
- Earning Date
- PSF 01-01-0001
- PLX 11-13-2025
- Dividend Yield
- PSF 7.69%
- PLX N/A
- EPS Growth
- PSF N/A
- PLX N/A
- EPS
- PSF N/A
- PLX 0.07
- Revenue
- PSF N/A
- PLX $61,840,000.00
- Revenue This Year
- PSF N/A
- PLX $14.53
- Revenue Next Year
- PSF N/A
- PLX $75.77
- P/E Ratio
- PSF N/A
- PLX $25.34
- Revenue Growth
- PSF N/A
- PLX 35.41
- 52 Week Low
- PSF $16.00
- PLX $1.32
- 52 Week High
- PSF $20.19
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- PSF 28.77
- PLX 31.66
- Support Level
- PSF $20.71
- PLX $1.70
- Resistance Level
- PSF $20.36
- PLX $1.93
- Average True Range (ATR)
- PSF 0.17
- PLX 0.14
- MACD
- PSF -0.09
- PLX -0.06
- Stochastic Oscillator
- PSF 14.29
- PLX 6.47
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.